Clinical Trial Update: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 study of CC-93269, a BCMA x CD3 T cell engaging antibody, in relapsed and refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-93269

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED